Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$20.99 USD
-0.38 (-1.78%)
Updated Jul 17, 2024 04:00 PM ET
After-Market: $21.02 +0.03 (0.14%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 81 - 100 ( 722 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Positive CHMP Opinion for EXPAREL in Children 6yo+, EU Approval Likely in Nov.
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Positive Results from Second Ph3 of EXPAREL/LENB; sNDA On-Track for Q1:23
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August Preliminary Sales Show +14.2% Month-over-Month and +12.8% YoY Growth
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Positive Topline Results from First Ph3 of EXPAREL/LENB; sNDA in Early 2023
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
July Preliminary Sales; Highlights from Wedbush Fireside Chat
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2: EXPAREL Excels Despite Headwinds; Progress Toward Product Expansion
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
2Q22: Solid Performance Excluding Resolved Manufacturing Hiccup; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Strong Q2 Prelim Sales Amid Pockets of Persistent Pandemic Headwinds
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department